Navigation Links
ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimer's disease clinical trials
Date:9/21/2009

GENEVA, Sept. 21 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

"With sufficient quantities of ANAVEX 2-73 in hand we are an important step closer to the commencement of Phase I clinical trials, which are scheduled to begin in early 2010," said Dr. Herve de Kergrohen, CEO of ANAVEX. "This lead drug candidate shows potential to alter the course of Alzheimer's disease by using sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease."

ANAVEX will shortly announce the selection of the Contract Research Organization (CRO) in charge of carrying out its Phase I clinical trials. Phase I is the stage at which testing moves to humans. Trials are designed to confirm the drug's safety and determine its tolerability in humans. Pharmacokinetics (the mechanisms of absorption and distribution of the drug, the rate at which a drug begins to act and the duration of its effect, as well as chemical changes of the substance in the body) and pharmacodynamics (physiological effects of drugs on the body, mechanisms of action and relationship between drug concentration and effect) are also studied during Phase I. ANAVEX 2-73 has already demonstrated powerful neuroprotective, anti-amnesic, anti-convulsive and anti-depressive activity in animal models. It also exhibited an excellent safety profile and therapeutic activity at very low doses.

The two kilograms of ANAVEX 2-73 was manufactured by Syntagon AB ("Syntagon") under GMP conditions, the quality assurance system required in the production of medicinal products. Syntagon developed a five-step synthetic procedure that achieved excellent yields in terms of the quantity of the compound that was produced and delivered it to ANAVEX on time.
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
8. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
9. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... Financing Provides Capital to Complete EVEREST Pivotal Study and Begin ... European Commercialization ... Investors, MENLO PARK, Calif., Dec. 4 Evalve, Inc., the leader ... that it had successfully completed a $60 million Series D,financing. BBT Fund ...
... Bivalirudin lowers bleeding risk for patients undergoing bypass, study ... newer kind of anticlotting drug is safe over the ... heart attacks. , The drug, a "direct thrombin inhibitor" ... during cardiac procedures such as bypass surgery. , "We ...
... some truth to the popular wisdom that plump babies are ... people who had a low birth weight are more likely ... found that even people who had just mild or moderate ... smaller babies than those who had better mental health, said ...
... of New Orleans residents in months after the disaster, study ... the people living in New Orleans and about one-quarter of ... signs of a mood or anxiety disorder five to seven ... Researchers surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , ...
... TARRYTOWN, N.Y., Dec. 4 EpiCept Corporation,(Nasdaq and OMX ... offering of 3,333,333 million shares of its common stock ... to approximately 1,666,667,million shares of common stock at an ... $4.7 million in net proceeds from the,offering. Rodman & ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) announced ... assets constituting its Biologics strategic business unit ... of Biotest,AG, for $185 million in cash. ... has acquired or will acquire the Biologics ...
Cached Medicine News:Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 2Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 3Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Smaller babies more prone to depression, anxiety later on 2Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 2Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 3
... & Nephew offers a wide variety of ... available in both partially threaded and fully ... are the 5.5 and 7.0 mm products. ... the surgeon's job a little easier. Ratchet ...
... Nailing System is one of the first ... for either an antegrade or a retrograde ... , ,Stryker Orthopaedics Trauma has now created ... together all the capabilities and benefits of ...
... Humeral Nail System has been designed to ... noninvasive treatments have historically failed to give ... blend of strength and flexibility. Ideally suited ... titanium alloy is twice that of stainless ...
... nailing techniques have largely replaced the use of plates ... The use of rods or pins in the forearm ... has been no way to lock the pins or ... a non-locked nail is back out of the implant. ...
Medicine Products: